Cytoprotection with amifostine in the simultaneous radio-chemotherapy of recurrent head and neck cancer;Zytoprotektion mit amifostin im rahmen der radiochemotherapie bei vorbestrahlten kopf-hals-karzinomen

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL.4, 1999, Pages 37-40

  Büntzel, Jens ^a,d   Glatzel, Michael ^b   Schuth, Julius ^c   Weinaug, Ronald ^a   Küttner, Klaus ^a   Fröhlich, Dietmar ^b  

^a Klin Hals Nasen Ohren Heilkunde   (Germany)

^b Klin Strahlenlherapie am Z   (Germany)

^c Essex Pharma   (Germany)

^d Zentralklinikum gGmbH Sudthuringen   (Germany)

Author keywords

Amifostine; Carboplatin; Head and neck carcinoma; Re irradiation; Simultaneous radio chemotherapy

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DYSPHAGIA; HEAD CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NECK CANCER; RADIATION DOSE; RADIATION PROTECTION; TUMOR LOCALIZATION; XEROSTOMIA;

ADULT; AGED; AMIFOSTINE; ANEMIA; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARBOPLATIN; COMBINED MODALITY THERAPY; CYTOPROTECTION; DEGLUTITION DISORDERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSTOPERATIVE CARE; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; STOMATITIS; THROMBOCYTOPENIA; TIME FACTORS; XEROSTOMIA;

EID: 0344718560     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Benchalal M, Bachaud JM, Francois P, et al. Hyperfractionation in the reirradiation of head and neck cancers. Results of a pilot study. Radiother Oncol 1995;36:203-10.
2. Büntzel J, Glatzel M, Küttner K, et al. Ethyol (amifostin) provides multilineage hematoprotection and protection against non-hematologic toxicities induced by radiochemotherapy (RCT) of head and neck cancer. Blood 1996;88:Suppl 1,Part I:448a.
3. Büntzel J, Glatzel M, Schuth J, et al. Einsatz von Amifostin bei simultaner Radio-Chemotherapie von HNO-Tumoren - eine Phase I/II Studie. Dtsch Z Onkol 1996;28:42-9.
4. Büntzel J, Küttner K, Russell L, et al. Intensive radiochemotherapy (RCT) with amifostine (A) in head and neck (H&N) cancer. Eur J Cancer 1997;33:Suppl 8:517-8.
5. Busch M, Schymura B, Dühmke E. Cytoprotection with amifostine in recurrent head and neck cancer. Proc Am Soc Clin Oncol 1997;16:397a.
6. Busch M, Schymura B, Hollenhorst H, et al. Zytoprotektion mit Amifostin (Ethyol) in der Tumortherapie. Strahlenther Onkol 1996;172:Sonderheft 1:70.
7. Giglio R, Mickiewicz E, Pradier E. et al. Alternating chemotherapy (CT) + radiotherapy (RT) with amifostine (A) protection for head and neck cancer (HN). Early stop of a randomized trial. Proc Am Soc Clin Oncol 1997;16:384a.
8. Kemp G, Rose P, Lurain J. et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-12.
9. McDonald S, Meyerowitz C, Smudzin T, et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29:747-54.
10. Planting AST. Vermorken JB, Catimel G, et al. Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Proc Am Soc Clin Oncol 1996;15:314.
11. Pratt NE, Sodicoff M, Liss J, et al. Radioprotection of the rat parotid gland by WR-2721: morphology at 60 days post-irradiation. Int J Radiat Oncol Biol Phys 1980;6:431-5.
12. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastin in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996;14:1913-21.
13. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994;29:687-98.
14. Takahashi I, Mitsuhashi N, Itoh J, et al. [Clinical use of radioprotector amifostine (YM-08310)]. Nippon Igaku Hoshasen Gakkai Zasshi 1984;44:1396-404.
15. Takahashi I, Nagai T, Miyaishi K, et al. Clinical study of the radioprotective effects of amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 1986;12:935-8.
16. Trog D. Füller J, Wendt T. et al. Reduktion gastrointestinaler Akuttoxizität unter Amifostingabe (Ethyol®) bei kombinierter Radio-Chemotherapie (RCT) lokal fortgeschrittener Tumoren im Kopf-Hals-Bereich (HNO). Strahlenther Onkol 1996;172:Sonderheft 1:45.
17. Yokes EE, Athanasiadis I. Chemotherapy of squamous cell carcinoma of head and neck: the futurte is now. Ann Oncol 1996;7:15-29.
18. Vokes EE, Harraf DJ, Weichselbaum RR. Re-irradiation with concurrent hemotherapy for regionally recurrent head and neck cancer (HNC). Ann Oncol 1996;7:Suppl 5:80.
19. Wang CC. To reirradiate or not to reirradiate? Int J Radiat Oncol 1994;29:913.